{"analyses":[{"ciLowerLimit":"10.1","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"18.7","groupIds":["OG000","OG001"],"nonInferiorityComment":"Based on Miettinen \\& Nurminen method stratified by Stage (II versus III), TPS (\\>=50% versus \\<50%), Histology (Squamous versus Non-squamous) and Region (East-Asia versus non-East Asia).","nonInferiorityType":"OTHER","pValue":"<0.00001","paramType":"Difference in Pertentage","paramValue":"14.2","statisticalMethod":"Stratified Miettinen and Nurminen"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.5","upperLimit":"22.3","value":"18.1"},{"groupId":"OG001","lowerLimit":"2.3","upperLimit":"6.4","value":"4.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"397"},{"groupId":"OG001","value":"400"}],"units":"Participants"}],"description":"pCR rate is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes following completion of neoadjuvant therapy. The pCR rates as assessed by blinded independent pathologist are presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of pembrolizumab \\[200 mg, intravenous (IV); given on cycle day 1\\] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin \\[75 mg/m\\^2, IV; given on cycle day 1\\] and either Gemcitabine \\[1000 mg/m\\^2, IV; given on cycle days 1 and 8\\] or Pemetrexed \\[500 mg/m\\^2, IV; given on cycle day 1\\].\n\nAdjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab \\[200 mg, IV; given on cycle day 1\\].","id":"OG000","title":"NAC + Neoadjuvant/Adjuvant Pembrolizumab"},{"description":"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of placebo \\[normal saline, IV; given on cycle day 1\\] in combination with platinum doublet NAC, consisting of cisplatin \\[75 mg/m\\^2, IV; given on cycle day 1\\] and either Gemcitabine \\[1000 mg/m\\^2, IV; given on cycle days 1 and 8\\] or Pemetrexed \\[500 mg/m\\^2, IV; given on cycle day 1\\].\n\nAdjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo \\[normal saline, IV; given on cycle day 1\\].","id":"OG001","title":"NAC + Neoadjuvant/Adjuvant Placebo"}],"paramType":"NUMBER","populationDescription":"The analysis population consisted of all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 8 weeks following completion of neoadjuvant treatment (up to Study Week 20)","title":"Pathological Complete Response (pCR) Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}